Active Ingredient History
Bromfenac is a topical, nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. It is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2. The most commonly reported adverse reactions in 3 to 8% of patients were anterior chamber inflammation, foreign body sensation, eye pain, photophobia and vision blurred. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Inflammation (approved 2013)
Pain (approved 2013)
Cataract (Phase 4)
Conjunctivitis, Allergic (Phase 3)
Diabetes Mellitus (Phase 3)
Dry Eye Syndromes (Phase 4)
Exfoliation Syndrome (Phase 4)
Eye Diseases (Phase 3)
Familial Exudative Vitreoretinopathies (Phase 2)
General Surgery (Phase 4)
Glaucoma (Phase 4)
Inflammation (Phase 4)
Intraocular Pressure (Phase 4)
Intravitreal Injections (Phase 4)
Lens Diseases (Phase 3)
Macular Degeneration (Phase 2)
Macular Edema (Phase 4)
Myopia (Phase 4)
Pain (Phase 4)
Postoperative Complications (Phase 3)
Presbyopia (Phase 1)
Pseudophakia (Phase 4)
Pterygium (Phase 4)
Retinal Diseases (Phase 4)
Vision, Ocular (Phase 4)
Vitrectomy (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue